Previous analyses 1, 2 indicated that acute gastroenteritis accounted for more than 20 million episodes of diarrhea and 1.5 million outpatient visits annually in the United States by children younger than 5 years.
#Remove iglasses trial registration#
Trial Registration Identifier: NCT00689312 There were differences in the identification of the best-tasting solution, with Pedialyte selected by 35 of 66 children (53%), Pediatric Electrolyte by 26 of 66 children (39%), and Enfalyte by 5 of 66 children (8%) ( P < .001).Ĭonclusion Sucralose-sweetened oral rehydration solutions (Pedialyte and Pediatric Electrolyte) were significantly more palatable than was a comparable rice-based solution (Enfalyte). The proportion of children who would drink each solution in the future varied significantly between Enfalyte and Pediatric Electrolyte (odds ratio, 0.22 95% confidence interval, 0.11-0.46) and between Enfalyte and Pedialyte (0.38 0.25-0.57). Differences in mean volume consumed were not significant (Enfalyte, 15 mL Pediatric Electrolyte, 17 mL and Pedialyte, 22 mL ). Unadjusted values were 65 mm for Pedialyte, 58 mm for Pediatric Electrolyte, and 23 mm for Enfalyte. A significant carryover effect was detected for taste scores ( P = .03), which were significantly different with and without adjustment for the carryover effect ( P < .001). Results All enrolled patients completed all 3 study periods. Secondary outcome measures were volume consumed, willingness to consume each liquid again, and the most favored liquid. Main Outcome Measures The primary outcome was each child's rating of taste as measured on a 100-mm visual analog scale (worst taste, 0 mm best taste, 100 mm). Intervention Each participant consumed as much of each solution as they desired during a 15-minute period. Participants Sixty-six children aged 5 to 10 years with concerns unrelated to the gastrointestinal tract. Setting Emergency department of a tertiary care pediatric hospital. Objective To compare the palatability of 3 oral rehydration solutions.ĭesign Prospective, blinded, randomized, 3-period, 3-treatment crossover trial. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 kommentar(er)
